Charles Sawyers, Chair of Memorial Sloan-Kettering’s Human Oncology and Pathogenesis Program, is a recipient of the inaugural $3 million prize for groundbreaking achievements in scientific research.
Researchers have clarified the process by which developing nerve cells are directed to specialize into distinct parts.
Researchers have shed light on how an important treatment for early-stage bladder cancer enters cancer cells to eradicate them.
Scientists have identified genes and biological mechanisms that one day could be targeted with drugs to stop kidney cancer from spreading to the bone, brain, or other organs.
Memorial Sloan-Kettering researchers have reported a new method that could allow the development of more-specific, cell-based therapies for cancer.
Recent findings by Memorial Sloan-Kettering immunologists might one day pave the way for new strategies to control a range of diseases, including autoimmune disorders and cancer.
Physician-scientists Michel Sadelain and Jedd Wolchok have been appointed to a new research team dedicated to investigating ways to harness the immune system to fight cancer.
Methods to generate stem cells have given scientists new ways to study some diseases and identify potential drugs, and could one day be used to rebuild diseased or damaged tissues in patients.
Charles Sawyers, Chair of Memorial Sloan-Kettering’s Human Oncology and Pathogenesis Program, is widely recognized as someone who is revolutionizing the molecular treatment of cancer.
At Memorial Sloan-Kettering, new technologies to study gene changes in cancer cells are accelerating the development and implementation of more-effective treatments.